Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17337266 | 0.85 | ALDH1A1 (0.34) | ALDH1A1MAPTSMN1; SMN2KDM4EKMT2A | |
| SCHEMBL17337269 | 0.85 | ALDH1A1 (0.34) | ALDH1A1MAPTSMN1; SMN2KDM4EKMT2A | |
| SCHEMBL23837376 | 0.84 | SMYD3 (0.34) | MAPT | |
| SCHEMBL22667381 | 0.83 | MTNR1A (0.41) | ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL20053206 | 0.83 | SMYD3 (0.38) | ALDH1A1 | |
| SCHEMBL19228090 | 0.82 | KMT2A (0.39) | KMT2A | |
| SCHEMBL18797980 | 0.82 | NAMPT (0.35) | MAPT | |
| SCHEMBL23130007 | 0.81 | AAK1 (0.32) | MAPT | |
| SCHEMBL19663642 | 0.81 | MAPT (0.34) | MAPT | |
| SCHEMBL19663800 | 0.81 | HTT (0.42) | ALDH1A1SMN1; SMN2KDM4EKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3882252-A1 | BETA-LACTAMASE INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2021-09-22 | — | — | EP | disclosed |